Reuters logo
BRIEF-SyntheticMR's feature REMyDI is now CE-marked for clinical use in Europe
April 19, 2017 / 11:04 AM / 7 months ago

BRIEF-SyntheticMR's feature REMyDI is now CE-marked for clinical use in Europe

April 19 - SYNTHETICMR AB:

* ANNOUNCED ON TUESDAY THAT ITS FEATURE REMYDI IS NOW CE-MARKED FOR CLINICAL USE IN EUROPE

* REMYDI PROVIDES AUTOMATIC MEASUREMENT OF MYELIN VOLUME IN THE BRAIN

* REMYDI IS NOW AVAILABLE IN THE SYMRI NEURO REMYDI PACKAGE

* SYMRI IS A CE-MARKED PRODUCT AND IS FDA 510(K) PENDING

Source text: bit.ly/2pfRuSr

Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below